Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 1,400 Shares

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 1,400 shares at an average price of $39.19, decreasing its ownership by 0.09% and leaving it with approximately 1,637,660 shares valued at about $64.2 million.
• The stock's recent trading price reached $37.46, with a market cap of $256.75 million, while its 52-week range is between $2.62 and $65.80.
• Analysts have rated Vor Biopharma as a "Moderate Buy" with an average target price of $113.83, indicating strong future potential.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 1,400 shares of the company's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $39.19, for a total transaction of $54,866.00. Following the completion of the sale, the insider directly owned 1,637,660 shares of the company's stock, valued at approximately $64,179,895.40. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The shares were sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The shares were sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The shares were sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The shares were sold at an average price of $40.00, for a total transaction of $898,440.00.

Vor Biopharma Price Performance

Shares of VOR stock traded up $0.78 during mid-day trading on Friday, hitting $37.46. 390,504 shares of the stock traded hands, compared to its average volume of 389,991. The stock has a market cap of $256.75 million, a P/E ratio of -22.70 and a beta of 2.05. The stock's fifty day moving average is $38.88 and its two-hundred day moving average is $24.15. Vor Biopharma Inc. has a 52-week low of $2.62 and a 52-week high of $65.80.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors have recently added to or reduced their stakes in the stock. Money Concepts Capital Corp grew its stake in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares during the period. Goldman Sachs Group Inc. grew its stake in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares during the period. XTX Topco Ltd acquired a new stake in Vor Biopharma in the 2nd quarter valued at $66,000. OMERS ADMINISTRATION Corp acquired a new stake in Vor Biopharma in the 1st quarter valued at $100,000. Finally, Jane Street Group LLC acquired a new stake in Vor Biopharma in the 1st quarter valued at $140,000. Institutional investors and hedge funds own 97.29% of the company's stock.

Analysts Set New Price Targets

VOR has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Vor Biopharma in a research report on Thursday, August 14th. Stifel Nicolaus upgraded shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price objective on the stock in a report on Wednesday, September 24th. Finally, Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Vor Biopharma presently has an average rating of "Moderate Buy" and an average target price of $113.83.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.